It is time for Singapore to provide better patient care with improved infectious disease detection and personalised medicine. Now with the official opening of Delta-IBN Life Science and Diagnostics Lab at the Biopolis, we will have a lab that develops next-generation infectious disease detection kits through collaborative research projects undertaken by Delta, IBN, and local universities.
The factors that make this a promising collaboration are the strengths of IBN in medical diagnostics, microfluidic systems and biological assays, and Delta’s expertise in microelectronics, optical devices, and global operations. These dynamics will allow the Delta-IBN laboratory to speed up diagnostics processing time with the development of advanced technology like portable miniaturised all-in-one systems designed to provide the on-the-spot, real-time detection results that we need to provide innovative healthcare for the nation.
In the words of A*STAR Chairman Mr. Lim Chuan Poh , the Delta-IBN Life Science and Diagnostics Lab represents a strong commitment from Delta to establish a long-term partnership with IBN and to continually invest in R&D and advance technological innovations in Singapore.
The Delta-IBN Life Science and Diagnostic Lab is expected to have over 50 Delta staff, who will work on joint projects with IBN researchers. The lab has also started research programs with universities, such as Nanyang Technological University and the Singapore University of Technology and Design.
Background information from the press release
Delta, founded in 1971, is a global leader in power and thermal management solutions. Our mission statement, “To provide innovative, clean and energy-efficient solutions for a better tomorrow,” focuses our role in addressing key environmental issues such as global climate change. As an energy-saving solutions provider with core competencies in power electronics and in innovative research and development, Delta’s businesses encompass Power Electronics, Energy Management, and Smart Green Life. Delta has sales offices worldwide with manufacturing facilities and R&D centers in Taiwan, China, USA, Europe, Thailand, Japan, Singapore, India, Mexico and Brazil.
Delta has received many global awards and recognition for its business milestones, innovative technology and corporate social responsibility. Since 2011, Delta has been selected as a member of the prestigious Dow Jones Sustainability™ World Index (DJSI World) for 4 consecutive years. In 2014, Delta was ranked at the highest A-level of the Climate Performance Leadership Index (CPLI) of the Carbon Disclosure Project (CDP), and it was the only company from Greater China to be named to the CPLI from nearly 2,000 listed companies.
For more information, please link: www.deltaww.com
Established in 2003, the Institute of Bioengineering and Nanotechnology (IBN) is the world’s first bioengineering and nanotechnology research institute. IBN’s mission is to conduct multidisciplinary research across science, engineering, and medicine for breakthroughs to improve healthcare and quality of life.
IBN’s research activities are focused in the following areas:
- Nanomedicine, where fictionalised polymers, hydrogels and biologics are developed as therapeutics and carriers for the controlled release and targeted delivery of therapeutics to diseased cells and organs.
- Cell and Tissue Engineering, where biomimicking materials, stem cell technology, microfluidic systems and bioimaging tools are combined to develop novel approaches to regenerative medicine and artificial organs.
- Biodevices and Diagnostics, which involve nanotechnology and microfabricated platforms for high-throughput biomarker and drug screening, automated biologics synthesis, and rapid disease diagnosis.
- Green Chemistry and Energy, which encompass the green synthesis of chemicals and pharmaceuticals, catalytic conversion of biomass, use of carbon dioxide, and new nanocomposite materials for energy applications.
For more information about IBN, please visit: www.ibn.a-star.edu.sg.
The Agency for Science, Technology and Research (A*STAR) is Singapore’s leading public sector agency that fosters world-class scientific research and talent to drive economic growth and transform Singapore into a vibrant knowledge-based and innovation driven economy.
In line with its mission-oriented mandate, A*STAR spearheads research and development in fields that are essential to growing Singapore’s manufacturing sector and catalyzing new growth industries. A*STAR supports these economic clusters by providing intellectual, human and industrial capital to its partners in industry.
A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities, located in Biopolis and Fusionopolis, as well as their vicinity. These two R&D hubs house a bustling and diverse community of local and international research scientists and engineers from A*STAR’s research entities as well as a growing number of corporate laboratories.
For more information on A*STAR, please visit www.a-star.edu.sg.